News & Events
ElastiMed Signs Exclusive U.S. Distribution Agreement with Tactile Medical
Strategic distribution partnership brings ElastiMed’s compression device for the treatment of venous and lymphatic conditions to ambulatory Veterans Affairs patients across the United States
14 July 2026
Portfolio company ElastiMed Ltd. (“ElastiMed”), a commercial-stage medical device company, pioneering the use of Electroactive Polymer (EAP) technology in wearable therapeutic devices, has entered into an exclusive U.S. distribution agreement with Tactile Systems Technology, Inc. (“Tactile Medical”), a Nasdaq-listed medical technology company (Nasdaq: TCMD). Under the agreement, Tactile Medical will serve as ElastiMed’s exclusive U.S. distribution partner to bring MyoSleeve™, a discreet, wearable non-pneumatic compression device for the lower leg, to Department of Veterans Affairs (“VA”) and Department of Defense (“DoD”) patients at select VA and DoD facilities across the United States (“U.S.”).
The agreement marks a major milestone in ElastiMed’s U.S. commercial launch strategy, providing immediate access to a large, underserved patient population.
ElastiMed’s MyoSleeve combines clinical-grade compression with comfort and connectivity in a breakthrough, low-profile wearable device, intended to promote compliance and support optimal clinical outcomes for the treatment of venous and lymphatic conditions.
Partnering with Tactile Medical gives MyoSleeve a direct path to patients with chronic swelling who want to stay active while getting the treatment they need. It is the first ambulatory all-in-one, cable-free, clinical-grade solution for patients with venous and lymphatic conditions. This partnership enables the first commercial introduction of MyoSleeve through a trusted and market-leading medical device partner, with the infrastructure and scale to make a meaningful impact.
Omer Zelka, Chief Executive Officer of ElastiMed
This distribution agreement is the kind of validation event that can change the trajectory of a company. Tactile’s reach and infrastructure, combined with the innovation behind MyoSleeve, put us in a strong position to bring meaningful relief to patients who have been underserved for too long.
Dr. Amir Belson, ElastiMed’s Chairman
A commercial agreement with a Nasdaq-listed medical technology company is strong validation of ElastiMed’s technology and of Trendlines’ model of transforming early-stage innovations into commercial businesses, supporting long-term value creation for our shareholders.
Haim Brosh, CEO of The Trendlines Group
See More News
Escala Secures $4.5M in Funding to Accelerate Global Expansion of Its FDA-Approved Medical Device
Co-financing by the EIC Fund to ramp up women’s health solution to POP
Phytolon Secures Funding from Rich Products Ventures to Bring Natural Food Colors to Market
